PTK 2015 Banner 
2015 Peptalk M Banner 
2014 Archived Content

SHORT COURSE 1: TARGETING OF GPCRs WITH MONOCLONAL ANTIBODIES

 

Sunday, January 12 | 5:00-8:00 pm

 

While GPCRs (G protein-coupled receptors) are important therapeutic targets, it has been challenging to discover therapeutically relevant antibodies against them.  This course will examine different steps along the anti-GPCR antibody discovery pathway and highlight various approaches to accomplishing each step.  The topics to be covered include: antibody discovery, including methods to generate antibodies and antigen preparation; assays to evaluate antibody binding using cells expressing the GPCR of interest; and in vitro assays to measure functional activity of the antibody, including antagonism, agonism, or synergism/allosteric modulation using  chemotaxis, calcium, cAMP or other cell-based assays; and 4) review of promising GPCR targets and therapeutic antibodies currently in  clinical development.

 

The material to be presented in this short course includes:

  • Brief review of GPCRs, including structure, mechanism and role in diseases such as cancer, inflammation and metabolic disease
  • Methods for antibody discovery
  • in vitro assays for antibody characterization
  • Review of relevant kinetics, including agonism, antagonism and allosteric modulation
  • Review of GPCR-targeting antibodies in the clinic
  • Open discussion

 

Instructor:

Barbara Swanson, Ph.D., Director, Research, Sorrento Therapeutics, Inc.


Speaker Biography

BarbaraSwansonBarbara Swanson, Ph.D., Director, Research, Sorrento Therapeutics, Inc.

Barbara Swanson, Ph.D., is a Director of Research at Sorrento Therapeutics, where she leads the programs to discover therapeutic antibodies against GPCRs and to optimize therapeutic antibodies. In previous industrial positions she discovered antibodies against membrane-bound proteins including GPCRs. Using protein engineering techniques she has improved industrial enzymes, peptides and therapeutic antibodies, with several of her optimized antibodies in clinical trials. Dr. Swanson received her B.S. in Chemistry from MIT and her Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco.



«Back to Short Courses